VEGFA and Retinal hemorrhage: The ancillary studies of CLARITY revealed that aflibercept reduced retinal hemorrhages and intravitreal microvascular abnormalities but not venous beading at week 52, suggesting that VEGF would not have been involved in the pathophysiology of vein changes, or these anatomical changes may not have been improved in a relatively short period of 1 year (18).